Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Xianli Yin(Central South University), Dongfang Liu(Dalian Medical University), Haolan Lu, Lei Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Zhang(Janssen (Belgium)), John Gong, Jianming Xu(81th Hospital of PLA), Yanhong Deng(Sun Yat-sen University), Nong Xu(First Affiliated Hospital Zhejiang University), Xiaotong Song(Chinese Academy of Sciences)
Cited by 6
Related Papers
Regulatory T cells in cardiovascular diseases
|Nature Reviews Cardiology|2015|410
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|291